Healthcare >> Analyst Interviews >> December 5, 2001
KEITH ACKERMAN is First Vice President of Instinet Corporation, a
subsidiary of Reuters Plc. Mr. Ackerman has oversight of Instinet's
Research Unit, which has its own proprietary research teams and is
actively engaged in various business partnerships with third party
information/research providers on three continents. Prior to joining
Instinet Corporation, Mr. Ackerman served on the management team of
PriceWaterhouse Coopers' strategy/business development unit and,
previously, as President of a wholly owned Price Waterhouse subsidiary.
In addition, Mr. Ackerman has worked for two New York Stock Exchange
member firms and was engaged in, among other things, initial public
offerings and bridge financings. He holds an MBA from the Fordham
University Graduate School of Business and a BA from Tufts University. Profile
HUGH JONES leads Datamonitor's healthcare practice on the global level.
Prior to his current position as Managing Director, Healthcare, he spent
the past two years building the analytical capabilities of the Firm as
the Global Director of Analysis. In addition to his managerial roles,
Mr. Jones participates frequently on both syndicated and custom
engagements in areas such as portfolio optimization, field force
structure, market assessments, product launch strategy, and multiple
eHealth issues. Prior to Datamonitor, Mr. Jones was with Deloitte
Consulting, where he concentrated on corporate and marketing strategy
for leading life science companies. He holds a BA from Yale University
and an MBA from the University of Michigan. Profile
TWST: Hugh, tell us about what's going on in the pharmaceutical industrytoday.
Mr. Jones: I think that the industry's faced with a growing number of
important issues that it has been trying